The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20061120: Pardus European Special Opportunities Master Fund L.P.; Visteon Corp.
0606017 Informal Interpretation
0606001 Informal Interpretation
Latino Quimica-Amtex S.A., et al. v. Atofina S.A. et al.
20061125: Level 3 Communications, Inc.; TelCove, Inc.
20061124: Tom L. Ward; N. Malone Mitchell, 3rd
0606006 Informal Interpretation
0606007 Informal Interpretation
FTC and Department of Justice Comments to Hon. Helene E. Weinstein Regarding New York A.B. A05596 to Establish that Certain Services Related to Real Estate Transactions May be Provided Only by Attorneys
Business Opportunity Rule - 16 CFR Part 437 (Extending Comment Period on Proposed Rule)
20061064: Merck & Co., Inc.; GlycoFi, Inc.
20060573: GATX Corporation; Oglebay Norton Company
0605031 Informal Interpretation
Johnson & Johnson, In the Matter of
The consent order protects competition in three medical device product markets affected by Johnson & Johnson’s proposed $25.4 billion acquisition of Guidant Corporation. Under the terms of the order, J&J is required to 1) grant to a third party a 6 fully paid-up, non-exclusive, irrevocable license, enabling that third party to make and sell drug eluting stents with the Rapid Exchange delivery system, 2) divest to a third party J&J’s endoscopic vessel harvesting product line, and 3) end its agreement to distribute Novare Surgical System, Inc.’s proximal anastomotic assist device. On May 31st, 2006 the Commission granted a petition filed by Johnson and Johnson Corporation, requesting that the FTC reopen and set aside the entire decision and order concerning the proposed acquisition of Guidant Corporation.